EGFR mutational status in lung adenocarcinoma: Staging implications or continuous evolution?

J Thorac Cardiovasc Surg. 2017 Nov;154(5):1766-1767. doi: 10.1016/j.jtcvs.2017.07.053. Epub 2017 Aug 14.

Authors

Winifred M Lo¹, R Taylor Ripley²

Affiliations

¹ Thoracic and GI Oncology Branch, National Cancer Institute, CCR/NIH, Bethesda, Md.
² Thoracic and GI Oncology Branch, National Cancer Institute, CCR/NIH, Bethesda, Md. Electronic address: taylor.ripley@nih.gov.

PMID: 28870400
DOI: 10.1016/j.jtcvs.2017.07.053

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma of Lung*
Adenocarcinoma*
ErbB Receptors
Humans
Mutation
Prognosis

Substances

EGFR protein, human
ErbB Receptors